Back to top
more

Akcea Therapeutics, Inc. (AKCA)

(Delayed Data from NSDQ)

$19.26 USD

19.26
163,119

+0.03 (0.16%)

Updated Nov 13, 2019 03:57 PM ET

After-Market: $19.27 +0.01 (0.05%) 5:33 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.51%
17.57%
9.27%
4.95%
1.80%
10.51%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

D Value | C Growth | A Momentum | C VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Akcea Therapeutics (AKCA) Reports Q3 Loss, Tops Revenue Estimates

Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of 38.18% and 39.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

AKCA

Zacks Equity Research

Will Akcea Therapeutics (AKCA) Report Negative Earnings Next Week? What You Should Know

Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AKCA

Zacks Equity Research

Akcea Therapeutics (AKCA) Upgraded to Strong Buy: Here's Why

Akcea Therapeutics (AKCA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AKCA

Zacks Equity Research

What's in Store for Align Technology's (ALGN) Q3 Earnings?

We are optimistic that Align Technology's (ALGN) Invisalign product portfolio has shown continued strength in the third quarter.

VRTX ALGN XRAY AKCA

Zacks Equity Research

Will New Alliances Aid Quest Diagnostics (DGX) Q3 Earnings?

Quest Diagnostics (DGX) is likely to have retained its two-pronged agenda to accelerate growth and drive operational excellence in the third quarter.

VRTX DGX XRAY AKCA

Zacks Equity Research

Can Sequencing Products Drive Illumina's (ILMN) Q3 Earnings?

Illumina (ILMN) is taking a cautious approach after a disappointing second quarter.

ILMN ADUS AKCA DCPH

Zacks Equity Research

What's in Store for Edwards Lifesciences' (EW) Q3 Earnings?

The recent full-market launch of the HemoSphere platform with the FloTrac System and Acumen Hypotension Predictive Index should reflect in Edwards Lifesciences' (EW) third-quarter results.

EW VRTX XRAY AKCA

Zacks Equity Research

Can Structural Heart Strength Aid Abbott (ABT) Q3 Earnings?

Abbott (ABT) has been growing popular with developments in its flagship, market leading device for the treatment of mitral regurgitation, MitraClip.

ABT VRTX XRAY AKCA

Zacks Equity Research

Can Balanced Segmental Growth Aid Abbott (ABT) Q3 Earnings?

Abbott (ABT) is steadily gaining prominence for developments in its flagship, sensor-based continuous glucose monitoring (CGM) system of FreeStyle Libre.

ABT VRTX XRAY AKCA

Zacks Equity Research

Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates

Key highlights of the past week include label expansion of drugs, licensing deals and more.

PFE VSTM ACAD GILD IONS AKCA

Zacks Equity Research

Akcea Therapeutics Enters Oversold Territory

Akcea Therapeutics, Inc. (AKCA) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

AKCA

Zacks Equity Research

Akcea Therapeutics (AKCA) Reports Q2 Loss, Misses Revenue Estimates

Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of -5.26% and -34.59%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

AKCA

Zacks Equity Research

Will Akcea Therapeutics (AKCA) Report Negative Earnings Next Week? What You Should Know

Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AKCA

Zacks Equity Research

Akcea Therapeutics (AKCA) Q1 Earnings and Revenues Lag Estimates

Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of -72.58% and -7.55%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

AKCA

Zacks Equity Research

Akcea Therapeutics (AKCA) Earnings Expected to Grow: Should You Buy?

Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AKCA

Zacks Equity Research

Akcea Therapeutics (AKCA) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AKCA

Zacks Equity Research

Pfizer Gets FDA's Priority Review for Rare Disease Candidate

FDA grants priority review to Pfizer's (PFE) regulatory filing looking for approval of pipeline candidate, tafamidis to treat transthyretin amyloid cardiomyopathy.

PFE ALNY IONS AKCA

Zacks Equity Research

Akcea Therapeutics (AKCA) Q2 Earnings Preview: Here's What to Look Out For

Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AKCA

Zacks Equity Research

Are Options Traders Betting on a Big Move in Akcea (AKCA) Stock?

Investors need to pay close attention to Akcea (AKCA) stock based on the movements in the options market lately.

AKCA

Zacks Equity Research

Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA

Regulatory and pipeline updates comprise some of the key developments in the biotech sector this week. These include Gilead's Yescarta approval in Europe.

AMGN GILD IONS KALA AKCA

Zacks Equity Research

Is the Options Market Predicting a Spike in Akcea Therapeutics (AKCA) Stock?

Investors need to pay close attention to Akcea Therapeutics (AKCA) stock based on the movements in the options market lately.

AKCA

Zacks Equity Research

Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates

It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.

ADXS AMGN ARRY IONS AKCA

Zacks Equity Research

Are Options Traders Betting on a Big Move in Akcea Therapeutics (AKCA) Stock?

Investors in Akcea Therapeutics (AKCA) need to pay close attention to the stock based on moves in the options market lately.

AKCA

Zacks Equity Research

Ionis Pharmaceuticals Retains Rights to Inotersen, Stock Up

Ionis Pharmaceuticals (IONS) will independently develop Inotersen and IONIS-FB-L Rx as GlaxoSmithKline declines its option on both drugs.

GSK ALNY IONS AKCA